secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2023-07-19T23:59:59+00:00
Accession:  0001140361-23-035245
Event type: other_material
Sentiment:  positive
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion shareholders approve sale of zagociguat/CY3018 assets and CEO stock issuance
--------------------------------------------------------------------------------

- Shareholders approved Asset Sale Proposal (95% for) to sell zagociguat (CY6463) and CY3018 programs per May 11 APA.
- Shareholders also approved Nasdaq Proposal (96% for) allowing conversion of Series A Preferred held by CEO Peter Hecht into common stock.
- Quorum of ~63% (1,515,929 shares) achieved; adjournment proposal not presented due to sufficient votes.
- Vote results enable closing of asset sale to JW Celtics Investment Corp. and JW Cycle Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000114036123035245/0001140361-23-035245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000114036123035245/brhc20056035_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-035245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer